Stockwatch: Cardinal rule adherence – HALO slips but Shire shines
This article was originally published in Scrip
Executive Summary
A cardinal rule in pharmaceutical drug development is that you never put the sales of an existing product at risk for a second generation product that may never exist. This is because you don't have to do much risk-adjustment for the sales of a product already on the market - it is real cash flow. However, because there are so many unknowns with a product early in development, you should significantly risk-adjust those cash flows, and not sacrifice the real ones, for the possible ones. Sure, you might get cannibalisation with both first and second generation products end up on the market, but that should be the only harm that one product does to another.
You may also be interested in...
Stock Watch: Is Johnson & Johnson Edging Away From Pharma?
J&J’s Medtech division outshone pharma while recently launched innovative products contributed minimally: it is to be hoped investors’ reactions to the first set of big pharma Q1 results will not set the tempo for earnings season.
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.